FDA-approved1,2Evidence: Smaller human trials

Rusfertide1

Also called Mimrylo1,2

Key takeaway

Rusfertide is a lab-made cyclic peptide that mimics hepcidin, the body’s iron-regulating hormone. It is the active ingredient in Mimrylo, which FDA approved in August 2026.1,2 Mimrylo is approved to treat excess red blood cells (erythrocytosis) in adults with polycythemia vera.1 In the randomized, placebo-controlled VERIFY trial of 293 adults described in the label, 77% of patients given rusfertide and 33% given placebo avoided becoming eligible for blood removal (phlebotomy) between weeks 20 and 32.1

Rusfertide at a glance

What it isA synthetic cyclic peptide that mimics the hormone hepcidin, according to the Mimrylo label.1
FDA statusFDA-approved. Drugs@FDA lists Mimrylo, NDA 220605, with an original approval date of August 28, 2026. The cited label has no boxed warning.1,2
Human evidenceOne randomized, double-blind, placebo-controlled Phase 3 trial (VERIFY) in 293 adults with polycythemia vera, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is rusfertide?

Rusfertide is a synthetic cyclic peptide held together by a disulfide bond, with a fatty-acid chain attached, according to the label, which describes it as a hepcidin mimetic.1

In the United States it is the active ingredient of Mimrylo, approved under NDA 220605, according to Drugs@FDA.2

How does rusfertide work?

The label states that rusfertide mimics hepcidin and blocks ferroportin, the protein that moves iron out of cells. Less iron is then available to make red blood cells, which lowers hematocrit, the share of blood made up of red cells.1

What do human studies show?

VERIFY, described in the label, randomized 293 adults with polycythemia vera who needed frequent phlebotomy despite standard care to rusfertide or placebo for 32 weeks.1

Between weeks 20 and 32, 113 of 147 patients (77%) given rusfertide and 48 of 146 (33%) given placebo did not become eligible for phlebotomy, the trial’s measure of response, according to the label.1

What the evidence base contains

  • Controlled human trial VERIFY (NCT05210790): a randomized, double-blind, placebo-controlled Phase 3 trial in 293 adults with polycythemia vera who needed frequent phlebotomy, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is rusfertide FDA-approved?

Yes. Drugs@FDA lists Mimrylo, application NDA 220605, with an original approval date of August 28, 2026.2

The Mimrylo label cited here (DailyMed SPL version 5, published November 11, 2026) states that it is indicated for the treatment of erythrocytosis in adults with polycythemia vera.1

The label has no boxed warning. Its warnings include new or worsening high platelet counts, local reactions where it is given and possible harm to a fetus based on animal data.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Rusfertide is not among them.3,4

Timeline

  1. FDA approves Mimrylo, NDA 220605, according to Drugs@FDA.2
  2. DailyMed publishes the Mimrylo label version cited on this page.1

What is still unknown?

Its longer-term effects: the randomized comparison with placebo described in the label lasted 32 weeks, after which patients could continue on open-label treatment.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Rusfertide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Rusfertide are a bounded selection, not every registration or paper about Rusfertide. For the years before Rusfertide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Rusfertide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Rusfertide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Mimrylo for erythrocytosis in polycythemia vera. In a randomized, placebo-controlled trial of 293 adults described in the label, more patients given rusfertide than placebo avoided becoming eligible for phlebotomy.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Rusfertide?

FDA-approved as Mimrylo for erythrocytosis in polycythemia vera. In a randomized, placebo-controlled trial of 293 adults described in the label, more patients given rusfertide than placebo avoided becoming eligible for phlebotomy.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
3
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Rusfertide for the treatment of polycythemia vera.↗Source date October 31, 2026
  2. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT05210790↗Source date October 19, 2026
  3. Literature metadata · added November 16, 2026

    VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.↗Source date October 13, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Rusfertide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

11Selected dated records
15Connected citations
3Populated source years2024–2026
3/4Record lanes present

Registered human studies

Trial composition

5 of 5 selected trial records include at least one phase value; 5 of 5 include a status value in the retained structured contract.

PhasesPhase 2 4Phase 3 1
Status at observationCompleted 2Active, not recruiting 1Not yet recruiting 1Recruiting 1

PubMed bibliography

Publication composition

5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 3Comment 2Letter 2Clinical Trial, Phase II 1Multicenter Study 1Research Support, Non-U.S. Gov't 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
11

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 11 dated records

Research hub

Explore the Rusfertide evidence record

Open all 11 records →
11Dated records
3Evidence types
11Cited public sources
3Source years

Change ledger

Recently changed for Rusfertide

Open all 11 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT04202965

PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.

PeptideScanner change date
November 16, 2026
Cited source date
August 20, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04767802

PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.

PeptideScanner change date
November 16, 2026
Cited source date
March 18, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05210790

PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.

PeptideScanner change date
November 16, 2026
Cited source date
October 19, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Rusfertide

Open the full research atlas →
PubMed5

5 with attributed title, venue, publication-date, and type metadata.

  1. Rusfertide for the treatment of polycythemia vera.Expert opinion on pharmacotherapy · 2026 10 31
  2. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 10 13
  3. Rusfertide for iron overload in haemochromatosis.The lancet. Gastroenterology & hepatology · 2024 Mar
Explore all selected literature →
ClinicalTrials.gov5

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05210790Registry update October 19, 2026 · current at observation
  2. NCT07648030Registry update October 2, 2026 · current at observation
  3. NCT07765602Registry update August 28, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span March 18, 2024 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
  • U.S. Department of Health and Human Services3
Dated updates connected to this profile · 11

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Rusfertide for the treatment of polycythemia vera.↗

    PubMed lists PMID 42958870 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-31 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05210790↗

    PeptideScanner retained ClinicalTrials.gov record NCT05210790 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was rusfertide.↗

  3. Literature metadata

    VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.↗

    PubMed lists PMID 42868322 in Journal of clinical oncology : official journal of the American Society of Clinical Oncology as Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07648030↗

    PeptideScanner retained ClinicalTrials.gov record NCT07648030 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was rusfertide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07765602↗

    PeptideScanner retained ClinicalTrials.gov record NCT07765602 at 2026-11-16T01:38:51.796Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was rusfertide.↗

  6. Regulatory

    Drugs@FDA application NDA220605↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 220605 with status AP dated 2026-08-28, and names rusfertide acetate among the application record's active ingredients.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT04202965↗

    PeptideScanner retained ClinicalTrials.gov record NCT04202965 at 2026-11-16T01:38:51.796Z. Its registry update date was 2025-08-20, and PeptideScanner's reviewed identity mapping was rusfertide.↗

  8. Literature metadata

    Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.↗

    PubMed lists PMID 37863080 in The lancet. Gastroenterology & hepatology as Clinical Trial, Phase II, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-17 (day precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Rusfertide for iron overload in haemochromatosis - Authors' reply.↗

    PubMed lists PMID 38340748 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Rusfertide for iron overload in haemochromatosis.↗

    PubMed lists PMID 38340749 in The lancet. Gastroenterology & hepatology as Letter, Comment, with publication-date metadata of 2024-03 (month precision). PeptideScanner associated the retained record with the identity slug rusfertide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT04767802↗

    PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    MIMRYLO (rusfertide) kit · SPL version 5 · published 2026-11-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: MIMRYLO (rusfertide acetate), NDA 220605 · original approval August 28, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026